Alliances
Shares of Arsanis, Inc. are inching up this afternoon following the company’s announcement of a licensing deal with Austria-based BB100, LLC, a subsidiary of Bravos Biosciences.
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.
Arvinas closed a $55 million Series C financing round. The funds will be used to advance Arvinas’ two lead cancer programs into the clinic.
Less than one year after it launched Cambridge, Mass.-based startup Sigilon Therapeutics struck a collaboration deal with Eli Lilly to develop encapsulated cell therapies for the potential treatment of type 1 diabetes.
Building on a four-year-old relationship Roche struck a deal to acquire a regenerative therapy program for multiple sclerosis from Inception Sciences, a drug discovery engine co-founded with Versant Ventures in 2011.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) launched an educational suite dubbed the “Parkinson’s Clinical Trial Companion.”
Pfizer, based in New York City, and Allogene Therapeutics, based in South San Francisco, entered into an asset contribution deal, as well as a $300 million Series A round.
More than a dozen advertisers, including Johnson & Johnson and Bayer, have boycotted the Fox News show, “The Ingraham Angle,” after its host, Laura Ingraham, 54, bullied high school student David Hogg.
Scott Smith, Celgene’s chief operating officer, abruptly resigned Monday. His decision to leave appears to be prompted by a restructuring of the company’s executive team.
Dermavant Sciences, a company founded by biotech guru Vivek Ramaswamy, tapped former GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer.
PRESS RELEASES